Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome (Q44517927)

3 December 2017

Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome (English)

1 reference

3 December 2017

1 reference

C J Glueck

1

1 reference

3 December 2017

Ranganath Papanna

2

1 reference

3 December 2017

Ping Wang

3

1 reference

3 December 2017

Naila Goldenberg

4

1 reference

3 December 2017

Luann Sieve-Smith

5

1 reference

3 December 2017

1 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

52

1 reference

3 December 2017

908-915

1 reference

3 December 2017

7

1 reference

Cardiovascular morbidity and mortality associated with the metabolic syndrome

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

New drug targets for type 2 diabetes and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Dietary treatment of the metabolic syndrome--the optimal diet.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Clinical assessment of body hair growth in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

The importance of diagnosing the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Coronary heart disease risk factors in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Cardiovascular risk in women with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Polycystic ovary syndrome is associated with endothelial dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Beneficial effects of metformin in normoglycemic morbidly obese adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900104-5

10.1016/S0026-0495(03)00104-5

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference